Skip to content
Thursday 13 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,772.67
-0.56%
DAX
26,299.74
-0.12%
CAC 40
8,650.56
-0.28%
STOXX 50
6,545.47
+0.18%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Monday 16 November 2020 5:20 pm  |  Updated:  Monday 16 November 2020 6:34 pm

Breaking: UK secures 5m doses of Moderna vaccine

By: Poppy Wood

Add as a preferred source on Google
The UK entered crunch talks with Moderna this afternoon to secure a vaccine supply

The UK has today secured 5m doses of Moderna’s coronavirus vaccine, which proved 95 per cent effective in late-stage clinical trials, the health secretary has announced.

Speaking at today’s Downing Street press conference, Matt Hancock said: “I can announce that we have today an initial agreement for 5m doses of the Moderna vaccine.”

The doses will mean enough to vaccinate around 2.5m people against coronavirus.

Hancock added that results from its preliminary trials was “excellent news”, and that the UK could expect the vaccine to be rolled out by the spring if proven safe.

It comes after ministers entered crunch talks with Moderna executives this afternoon in a bid to secure a UK supply, after breakthrough data was dampened by revelations that Britain was not on Moderna’s order books.

Dr Stephen Hoge, president of Moderna, followed by telling the BBC he hoped his firm would be able to supply “substantial quantities” of its coronavirus vaccine to Britain.

 

The results came hot on the heels of Pfizer’s breakthrough announcement last week that its experimental Covid vaccine proved 90 per cent effective in trials.

Although trials of the Moderna vaccine were smaller than the international ones held by Pfizer, the Moderna jab may prove easier to distribute globally because it does not have to be stored and transported at sub-zero temperatures.

It has been shown to last for up to 30 days in household fridges and at room temperature for up to 12 hours.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

So far, the UK has secured 355m doses of potential vaccines produced by seven different companies.

Business secretary Alok Sharma today said it was important that Britain spread its chances across a range of vaccines because vaccination across the population would not be achieved by a “one-size fits all” drug.

“The speed at which scientists around the world have worked on a vaccine has been incredible, and it is thanks to their ingenuity that we are on the cusp of one of the biggest scientific breakthroughs in recent years,” said Sharma.

“While this is exciting news, I urge the public to not be complacent — we are at a critical point in the pandemic and in order to save lives we must continue to follow guidance by maintaining social distancing, wearing face masks and washing our hands regularly.”

Kate Bingham, chair of the government’s Vaccine Taskforce, said: “Today’s news from Moderna is very encouraging. The Moderna mRNA vaccine has posted excellent efficacy data to date from its initial phase three readout.

“The government’s Vaccine Taskforce are pursuing a portfolio approach to obtaining vaccines for the UK across different vaccine formats, to maximise the chances of finding safe and effective vaccines.”

Hancock also announced the government will launch a network of 40 clinics across the UK to tackle Long Covid.

Half a million people in Britain are understood to be struggling with lingering symptoms of Covid-19, including fatigue, breathlessness and chest pain.

A study published yesterday by Coverscan found that 70 per cent of “low risk” individuals who had previously contracted coronavirus incurred lasting damage in one or more organs, including the heart, lungs, liver and pancreas.

Read more

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • It’s not just Jason Arday, most of sociology is a scam

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • Revolut takes flight with launch of new airport lounges

  • As it happened: FTSE 100 falls as Iran and US clash over Strait of Hormuz; Oil stockpiles ‘rapidly depleting’

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Magic Circle firm Linklaters sees partner profits soar to £2.5m after record year

    Legal
    Exterior of 20 Ropemaker, a modern London office building, showcasing its sleek architecture and urban setting.
  • Farage quits to stand in ‘people versus establishment’ by-election

    Politics
    George Cottrell and Nigel Farage engaging in a conversation at a political event, both dressed in formal attire.
  • Exclusive: Government to reject Reform’s offer to cover Farage by-election cost

    Politics
    Nigel Farage speaking at a podium, dressed in a suit, addressing an audience at a business conference event
  • Pubs to pour five million extra pints during England v Norway World Cup clash

    Hospitality
    Exciting World Cup action as players compete energetically on the field, showcasing intense athleticism and global sportsm...
  • Burnham should go on a ‘cost of doing business’ tour

    Economics
    Andy Burnham, Mayor of Greater Manchester, in a dark suit and glasses, listening intently at a wooden table.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook